DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma

Kenneth E. Fasanella, Alyssa Krasinskas, Karen E. Schoedel, Eizaburo Sasatomi, Adam Slivka, David C. Whitcomb, Michael Sanders, Laurentia Nodit, Stephen Raab, Kevin M. McGrath, N. Paul Ohori, Asif Khalid

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background/Aims: Preoperative distinction between pancreatic cancer (PC) and extrahepatic cholangiocarcinoma (CC) is desirable due to diverging management options, and to optimize enrollment into neoadjuvant trials. Methods: A single-center retrospective study of patients with PC or CC was undertaken. Four blinded pathologists reviewed all cases and reached a consensus diagnosis (PC or CC). Microdissection-based multiple microsatellite loss analysis and direct sequencing of K-ras oncogene was performed and compared for PC and CC. Results: Of 33 cases studied (17 males; 16 PC, 17 CC; 10 with primary sclerosing cholangitis), a K-ras mutation was present in 14/16 (87.5%) PC and 1/17 (5.9%) CC cases (p < 0.001), sensitivity and specificity were 87.5 and 94%, respectively. The mean fractional mutational rate was higher in PC (0.51; 95% CI 0.45-0.58) compared to CC (0.34; 95% CI 0.28-0.39, p < 0.001). Conclusions: The presence of a K-ras mutation in cytology specimens distinguishes PC from CC in this study.

Original languageEnglish (US)
Pages (from-to)429-433
Number of pages5
Issue number4
StatePublished - Oct 2010
Externally publishedYes


  • Cholangiocarcinoma
  • Endoscopic retrograde cholangiopancreatography
  • Endoscopic ultrasound
  • K-ras
  • Pancreatic cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Gastroenterology


Dive into the research topics of 'DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this